<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754360</url>
  </required_header>
  <id_info>
    <org_study_id>bakircaymzeren01</org_study_id>
    <nct_id>NCT04754360</nct_id>
  </id_info>
  <brief_title>Cut-off Values of 6-min Walk Test and Sit-to-stand Test for Determining Symptom Burden and Functional Impairment in Atrial Fibrillation</brief_title>
  <official_title>Cut-off Values of 6-min Walk Test and Sit-to-stand Test for Determining Symptom Burden and Functional Impairment in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Bakircay University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Izmir Bakircay University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cut-off values indicating higher symptom burden and impairment in health status in 6-min walk&#xD;
      test and 30-second sit-to-stand test in patients with atrial fibrillation will be determined&#xD;
      in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 6-min walk test (6MWT) is the most used field test for measuring functional impairment in&#xD;
      cardiopulmonary patients. However, to be able to objectively interpret 6MWT of a patient with&#xD;
      specific chronic condition, the distance walked in 6MWT should be compared to either a&#xD;
      healthy control group or a cut-off value that was specifically determined for that&#xD;
      population. Such cut-off values are present for 6MWT in several cardiopulmonary diseases&#xD;
      including COPD (350 m), heart failure (200 m) and pulmonary hypertension (400 m) for&#xD;
      identifying patients with high mortality, poor prognosis and/or poor health status, but there&#xD;
      is no cut-off value determined for atrial fibrillation (AF). The European Heart Rhythm&#xD;
      Association (EHRA) score is a practical measure for assessing symptom burden and functional&#xD;
      impairment caused by AF-related symptoms. While EHRA class 1 indicates asymptomatic patients,&#xD;
      EHRA class 2, 3 and 4 indicates higher severities of symptom burden and functional&#xD;
      impairment. Primary aim of this study is to determine a cut-off value in 6MWT for&#xD;
      discriminating between the asymptomatic and symptomatic AF patients according to EHRA&#xD;
      classification. In addition, a cut-off value for 30-second sit-to-stand test will be&#xD;
      determined in these patients as well, since sit-to-stand tests have gained a lot of interest&#xD;
      in the recent literature for practically evaluating functional status in various&#xD;
      cardiopulmonary conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">May 10, 2021</completion_date>
  <primary_completion_date type="Actual">May 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The European Heart Rhythm Association (EHRA) score</measure>
    <time_frame>At baseline</time_frame>
    <description>Functional impairment and symptom burden of the patients will be determined according to The European Heart Rhythm Association (EHRA) score. While EHRA class 1 indicates asymptomatic patients, EHRA class 2, 3 and 4 indicates higher severities of symptom burden and functional impairment, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-min walk distance</measure>
    <time_frame>At baseline</time_frame>
    <description>Distance walked in six minutes will be recorded. Test will be conducted according to the guideline of American Thoracic Society (ATS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of repetitions in 30-second sit-to-stand test</measure>
    <time_frame>At baseline</time_frame>
    <description>Participants will be asked to perform sit-to-stand maneuver as fast as possible for 30 seconds and the number of completed repetitions will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>At baseline</time_frame>
    <description>FVC will be measured using basic spirometry according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>At baseline</time_frame>
    <description>FEV1 will be measured using basic spirometry according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF)</measure>
    <time_frame>At baseline</time_frame>
    <description>PEF will be measured using basic spirometry according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum inspiratory pressure (MIP)</measure>
    <time_frame>At baseline</time_frame>
    <description>MIP will be measured using electronic mouth pressure meter according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum expiratory pressure (MEP)</measure>
    <time_frame>At baseline</time_frame>
    <description>MEP will be measured using electronic mouth pressure meter according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36</measure>
    <time_frame>At baseline</time_frame>
    <description>Short Form-36 questionnaire will be used to measure quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire - Short Form</measure>
    <time_frame>At baseline</time_frame>
    <description>International Physical Activity Questionnaire - Short Form will be used to measure physical activity level</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>Adult patients with atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of functional impairment</intervention_name>
    <description>Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of pulmonary function</intervention_name>
    <description>Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of quality of life</intervention_name>
    <description>Quality of life will be evaluated using Short Form-36 Questionnaire.</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of physical activity level</intervention_name>
    <description>Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with atrial fibrillation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Diagnosis of paroxysmal, persistant or permanent atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of heart failure or any chronic respiratory disease&#xD;
&#xD;
          -  Recent coronary bypass surgery&#xD;
&#xD;
          -  Previous heart valve surgery&#xD;
&#xD;
          -  Rheumatic valvular heart disease&#xD;
&#xD;
          -  Recent acute myocardial infarction&#xD;
&#xD;
          -  Having a pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul University-Cerrahpasa, Institute of Cardiology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Bakircay University</investigator_affiliation>
    <investigator_full_name>Melih Zeren</investigator_full_name>
    <investigator_title>Assist. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Symptomatology</keyword>
  <keyword>Functional impairment</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>6-min walk test</keyword>
  <keyword>Sit-to-stand test</keyword>
  <keyword>Cut-off value</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

